Annual Report FY 2024-25
The early 2020s marked a turning point for generative AI (GenAI), moving from academic research to one of the most transformative technologies. What began as experimentation has rapidly matured into practical, high-value applications.
At the center of this shift are foundational Large Language Models (LLMs) – a leap beyond narrow, task-specific AI. Further, with the release of GPT-3 in 2020, the world witnessed the scale and potential of LLMs to mimic human language. By 2022, ChatGPT showcased the ability of GenAI to engage in nuanced conversations, generate creative content, and perform knowledge-intensive tasks, sparking global interest.
Our engagement with AI began much earlier, well before GenAI became a mainstream theme. Positioned at the intersection of healthcare and technology, we have consistently embedded Artificial Intelligence (AI), Machine Learning (ML) and Natural Language Processing (NLP) across our solutions and services to enhance efficiency, accuracy, and impact.
Our suite of NEXT platforms have been delivering value across life sciences workstreams. For example, our modular content solutions leverage AI to improve the effectiveness and efficiency of pharma content all through the content supply chain - from content origination to production, evolution, adaptation and deployment. The NEXT MLR Review Automation platform substantially reduces the effort and time for medical and regulatory review of scientific content. Invisage™, our AI-powered hybrid omnichannel sales and marketing platform, optimizes go-to-market strategies and improves RoI. Our NEXT Adverse Event Management platform uses AI to quickly and accurately process reports of side effects from medicines – helping pharma teams respond faster, stay compliant, and put patient well-being first.
Across our broad spectrum of offerings, AI supports pattern recognition, summarization, translation, and automated tagging, enabling domain experts to focus on higher-value tasks. As GenAI became mainstream in 2023, we explored its potential and steadily embraced it. Through active experimentation and real-time deployment, we deepened our understanding, focusing on driving meaningful RoI.
Our GenAI framework is aimed at deploying GenAI purposefully across key life sciences functions – Commercial, Medical, Regulatory, and Safety.
Over the years, we have built deep capabilities in AI, ML and NLP – embedding these technologies into our platforms to drive automation and outcomes.
With the shift from traditional AI to generative and agentic AI, we have accelerated investments to align with the new paradigm. We restructured our product and engineering teams in line with GenAI’s evolution. A dedicated group monitors changes across the GenAI ecosystem – testing emerging tools, refining models, and making them available for seamless integration across our solutions.
Our first major investment in GenAI was the SME Workbench – a no-code platform that enables domain experts to build, test, and launch GenAI use cases independently. It accelerated adoption internally and provided clients with a template to scale GenAI across use cases. By 2024, the SME Workbench proved instrumental in supporting multiple organizations in setting up their own GenAI Centers of Excellence (CoEs).
We have adopted a GenAI-first mindset across our product development. Our offerings include:
We also integrated GenAI into our existing services across content creation, pharmacovigilance, regulatory writing, medical affairs, and analytics. From generating avatars and podcasts to improving literature surveillance and adverse event detection, our solutions deliver impactful outcomes, enabling life sciences companies to lead in a GenAI-enabled world.
The cornerstone of our GenAI vision is Cortex – a fully verticalized, modular GenAI platform built for the life sciences industry. Launched in FY 2024-25, Cortex enables domain experts to codify knowledge using a natural language interface, eliminating reliance on engineering teams. It also enables them to develop multiple agents and workflows that integrate with enterprise systems, leading to rapid development, accelerated scale up, reliable outcomes and better RoI.
Knowledge Engineering Interface: Embeds 25+ years of domain expertise into reusable knowledge graphs via a no-code, natural language interface
Multi-Agent Orchestration: Enables configurable, use case-specific AI workflows with seamless enterprise integration
Secure implementation: Handles proprietary data with strict separation and zero cross-pollination
LLM-Agnostic AI Agents: Modular agents that work across LLMs and evolve with advances in the ecosystem
Model Context Protocol (MCP): Supports agent interoperability and frictionless integration into client IT environments
Cortex is not just another GenAI tool – it is a platform powered by deep healthcare domain knowledge and designed for scale, governance, and precision. It empowers domain experts to drive GenAI development. By separating business logic from model dependency, Cortex ensures reliability, flexibility and rapid contextualization to the nuances required to drive business outcomes.
We meaningfully deploy Cortex and Cortex-based use cases across client ecosystems, enabling rapid innovation and value delivery. Our focus is to expand use cases and enhance GenAI integration across the life sciences value chain.
